QIAGEN has unveiled its latest innovation, the QIAseq Multimodal DNA/RNA Lib Kit, designed to revolutionize multiomics studies by streamlining the preparation of DNA and RNA libraries for next-generation sequencing (NGS) from a single sample. This breakthrough kit addresses the growing demand in the scientific community for more efficient methods to conduct multiomic research, crucial for unraveling the complexities of biological processes, particularly in diseases like cancer.
By integrating optimized chemistry for DNA and RNA simultaneously, the QIAseq Multimodal DNA/RNA Lib Kit offers a seamless and rapid workflow, eliminating the need for separate workflows and reducing sample material requirements, labor, and turnaround times. This advancement not only enhances efficiency but also facilitates the identification of potential biomarkers for diseases and therapeutic targets, ultimately advancing precision medicine and healthcare.
Researchers can utilize the kit to generate DNA-only or RNA-only libraries, catering to diverse experimental needs. It is the first multimodal kit compatible with various input samples, including blood, Formalin-Fixed Paraffin-Embedded (FFPE) samples, and cell-free DNA (cfDNA), making it particularly valuable in translational research, such as cancer studies, where different sample types are available. Moreover, its high sensitivity enables the detection of rare DNA and RNA variants.
The QIAseq Multimodal DNA/RNA Lib Kit is compatible with a wide range of sequencing platforms, including Illumina instruments and others like Element Aviti, Complete Genomics/MGI, Singular Genomics, and Ultima Genomics with an added conversion step. Its flexibility extends to target enrichment, where it can be used with QIAseq xHYB Human panels for Whole Exome Sequencing (WES) or targeted sequencing with custom-designed content, as well as hybrid capture panels from other providers.
By consolidating multiple workflows into a single kit, the QIAseq Multimodal DNA/RNA Lib Kit not only saves laboratory resources but also enhances efficiency in NGS laboratories. It joins QIAGEN’s expanding portfolio of NGS solutions, aimed at maximizing sequencing capacity, reducing turnaround times, and advancing biological research. With a focus on front-end sample processing and downstream bioinformatics, QIAGEN continues to deliver innovative NGS technologies for genomics, transcriptomics, epigenomics, and metagenomics applications, empowering researchers worldwide.
